Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 27, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 3, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001298709-26-000002
Filed / recorded
Mar 3, 2026, 11:30 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Krystal Biotech, Inc.
Issuer CIK
1711279
Ticker
KRYS
Reporting person
Krish S Krishnan
Relationship
Director, Officer, 10% owner
Officer title
President and CEO
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
Feb 27, 2026
Transaction code
M
Shares / units
5,725
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
17,175
Ownership form
Direct
Amendment
No
Footnotes from the filing
22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026.